Dr. H.C. Lui, Director of Eagle IP Limited, participated the 7th Asia Solar PV Industry Exhibition which it held at Shanghai World Expo Exhibition & Convention Centre.
我们的过去活动
Recommended Insights
Stealing Trade Secrets: How the Chinese Court Criminally Sentences Employees that Steal Trade Secrets - 2019 China’s Top 50 Representative IP Cases
2020年6月11日The theft of trade secrets has always been a deep concern of foreign companies thinking of doing business in China, whether it be sharing protocols with a manufacturing partner, providing technology details to a potential investor, or sharing results from an R&D collaboration. How can businesses ensure that employees do not steal secrets and share […]
阅读更多 >
China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision
2022年9月21日China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
阅读更多 >
Breaking: China Released New Implementation Measures for the New Patent Linkage System
2021年7月14日On July 4, 2021, China’s National Medical Products Administration (NMPA) and the China National Intellectual Property Administration (CNIPA) released details on the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage”), effective July 4, 2021. Below is a summary highlighting key provisions and changes from the draft measures. Creation of an […]
阅读更多 >
Compositions Limited by Use: A Cautionary Tale
2022年10月26日Section 4.2.3, Part II Chapter 10 of the CNIPA’s Examination Guidelines (“Guidelines”) stipulates that if the specification only discloses one property or use of a composition, the composition claim shall be drafted as a “composition limited by the function or the use”. Furthermore, it specifically states that “most pharmaceutical claims shall be drafted as claims […]
阅读更多 >